%0 Journal Article
%T Preface to Precision Dosing of Targeted Anti-Cancer Drugs
%A Andrew Rowland
%A (Email: andrew.rowland@flinders.edu.au ) Michael J. Sorich
%A (Email: michael.sorich@flinders.edu.au )
%J SCIE-indexed Journal
%D 2017
%R 10.21037/17572
%X Small molecule protein kinase inhibitors (KIs) and anti-neoplastic monoclonal antibodies (mAbs) are rapidly expanding classes of non-cytotoxic or ¡®targeted¡¯ antineoplastic drugs that are effective at treating numerous malignancies, including previously difficult to treat forms of cancers. However, variability in disposition causes inter-individual variability in drug exposure that is inadequately addressed by the standard fixed-dose schedule of administration (1). Accordingly, precision dosing has great potential to maximise therapeutic response, minimise adverse drug reactions (ADRs), and improve cost-effectiveness of these expensive drugs
%U http://tcr.amegroups.com/article/view/17572/html